Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis

Journal of Neurochemistry

Volumn 130, Issue 2, 2014, Pages 268-279

  Trager, Nicole ^a   Smith, Amena ^b   Wallace Iv, Gerald ^a   Azuma, Mitsuyoshi ^c   Inoue, Jun ^c   Beeson, Craig ^d   Haque, Azizul ^a   Banik, Naren L ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SENJU PHARMACEUTICAL CO LTD   (Japan)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

calpain; EAE; inflammation; multiple sclerosis

Indexed keywords

CALPAIN; CALPASTATIN; IMMUNOMODULATING AGENT; [1 [(1 BENZYL 3 CYCLOPROPYLAMINO 2,3 DIOXOPROPYL)CARBAMOYL] 3 METHYLBUTYL]CARBAMIC ACID 2 (2 METHOXYETHOXY)ETHYL ESTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; DRUG EFFICACY; ENZYME INHIBITION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HELPER CELL; IMMUNOMODULATION; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY CELL; MALE; MOUSE; MULTIPLE SCLEROSIS; MURINE MODEL; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPINAL CORD; SPINAL CORD NERVE CELL; SUPPRESSOR CELL; TH1 CELL; TH17 CELL;

MURINAE;

CALPAIN; EAE; INFLAMMATION; MULTIPLE SCLEROSIS;

ANIMALS; BLOTTING, WESTERN; CALPAIN; CARBAMATES; CELL PROLIFERATION; CELL SEPARATION; CYSTEINE PROTEINASE INHIBITORS; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN SITU NICK-END LABELING; MALE; MICE; MONOCYTES; MULTIPLE SCLEROSIS; NERVE DEGENERATION; REAL-TIME POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84904065488     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12659     Document Type: Article

References (55)

1. Azuma M., and, Shearer T. R., (2008) The role of calcium-activated protease calpain in experimental retinal pathology. Surv. Ophthalmol. 53, 150-163. (Pubitemid 351381557)
2. Banik N. L., Chakrabarti A. K., and, Hogan E. L., (1987) Distribution of calcium activated neutral proteinase (mM CANP) in myelin and cytosolic fractions in bovine brain white matter. Life Sci. 41, 1089-1095. (Pubitemid 17118953)
3. Banik N. L., Matzelle D. C., Gantt-Wilford G., Osborne A., and, Hogan E. L., (1997) Increased calpain content and progressive degradation of neurofilament protein in spinal cord injury. Brain Res. 752, 301-306. (Pubitemid 27143927)
4. Berlet H. H., (1987) Calcium-dependent neutral protease activity of myelin from bovine spinal cord: evidence for soluble cleavage products of myelin proteins. Neurosci. Lett. 73, 266-270. (Pubitemid 17223634)
5. Bjartmar C., and, Trapp B. D., (2001) Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr. Opin. Neurol. 14, 271-278. (Pubitemid 32510589)
6. Cuzzocrea S., McDonald M. C., Mazzon E., et al,. (2000) Calpain inhibitor I reduces the development of acute and chronic inflammation. Am. J. Pathol. 157, 2065-2079.
7. Das A., Sribnick E. A., Wingrave J. M., Del Re A. M., Woodward J. J., Appel S. H., Banik N. L., and, Ray S. K., (2005) Calpain activation in apoptosis of ventral spinal cord 4.1 (VSC4.1) motoneurons exposed to glutamate: calpain inhibition provides functional neuroprotection. J. Neurosci. Res. 81, 551-562. (Pubitemid 41297392)
8. Deshpande R. V., Goust J. M., Hogan E. L., and, Banik N. L., (1995) Calpain secreted by activated human lymphoid cells degrades myelin. J. Neurosci. Res. 42, 259-265.
9. Diaz-Sanchez M., Williams K., DeLuca G. C., and, Esiri M. M., (2006) Protein co-expression with axonal injury in multiple sclerosis plaques. Acta Neuropathol. 111, 289-299.
10. Fleming K. K., Bovaird J. A., Mosier M. C., Emerson M. R., LeVine S. M., and, Marquis J. G., (2005) Statistical analysis of data from studies on experimental autoimmune encephalomyelitis. J. Neuroimmunol. 170, 71-84. (Pubitemid 41740908)
11. Goebels N., Hofstetter H., Schmidt S., Brunner C., Wekerle H., and, Hohlfeld R., (2000) Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain 123 Pt 3, 508-518. (Pubitemid 30099536)
12. Guyton M. K., Wingrave J. M., Yallapragada A. V., Wilford G. G., Sribnick E. A., Matzelle D. D., Tyor W. R., Ray S. K., and, Banik N. L., (2005) Upregulation of calpain correlates with increased neurodegeneration in acute experimental auto-immune encephalomyelitis. J. Neurosci. Res. 81, 53-61. (Pubitemid 41139110)
13. Guyton M. K., Brahmachari S., Das A., Samantaray S., Inoue J., Azuma M., Ray S. K., and, Banik N. L., (2009) Inhibition of calpain attenuates encephalitogenicity of MBP-specific T cells. J. Neurochem. 110, 1895-1907.
14. Guyton M. K., Das A., Samantaray S., Wallace G. C. 4th, Butler J. T., Ray S. K., and, Banik N. L., (2010) Calpeptin attenuated inflammation, cell death, and axonal damage in animal model of multiple sclerosis. J. Neurosci. Res. 88, 2398-2408.
15. Harrington L. E., Hatton R. D., Mangan P. R., Turner H., Murphy T. L., Murphy K. M., and, Weaver C. T., (2005) Interleukin 17-producing CD4 + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6, 1123-1132. (Pubitemid 41541790)
16. Hassan-Smith G., and, Douglas M. R., (2011) Management and prognosis of multiple sclerosis. Br. J. Hosp. Med. (Lond) 72, M174-M176.
17. Hassen G. W., Feliberti J., Kesner L., Stracher A., and, Mokhtarian F., (2006) A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis. J. Neuroimmunol. 180, 135-146. (Pubitemid 44692330)
18. Hassen G. W., Feliberti J., Kesner L., Stracher A., and, Mokhtarian F., (2008) Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis. Brain Res. 1236, 206-215.
19. Hendry L., and, John S., (2004) Regulation of STAT signalling by proteolytic processing. Eur. J. Biochem. 271, 4613-4620. (Pubitemid 40065564)
20. Imam S. Z., Guyton M. K., Haque A., Vandenbark A., Tyor W. R., Ray S. K., and, Banik N. L., (2007) Increased calpain correlates with Th1 cytokine profile in PBMCs from MS patients. J. Neuroimmunol. 190, 139-145.
21. Issazadeh S., Ljungdahl A., Hojeberg B., Mustafa M., and, Olsson T., (1995) Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor alpha and tumor necrosis factor beta. J. Neuroimmunol. 61, 205-212.
22. Kennedy M. K., Torrance D. S., Picha K. S., and, Mohler K. M., (1992) Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol. 149, 2496-2505.
23. Kivisakk P., Mahad D. J., Callahan M. K., et al,. (2003) Human cerebrospinal fluid central memory CD4 + T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc. Natl Acad. Sci. USA 100, 8389-8394. (Pubitemid 36842555)
24. Kupina N. C., Nath R., Bernath E. E., Inoue J., Mitsuyoshi A., Yuen P. W., Wang K. K., and, Hall E. D., (2001) The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. J. Neurotrauma 18, 1229-1240. (Pubitemid 33062546)
25. Lassmann H., (2013) Multiple sclerosis: lessons from molecular neuropathology. Exp. Neurol. doi: 10.1016/j.expneurol.2013.12.003.
26. Lassmann H., and, Ransohoff R. M., (2004) The CD4-Th1 model for multiple sclerosis: a critical [correction of crucial] re-appraisal. Trends Immunol. 25, 132-137. (Pubitemid 38249486)
27. Medveczky P., Antal J., Patthy A., Kekesi K., Juhasz G., Szilagyi L., and, Graf L., (2006) Myelin basic protein, an autoantigen in multiple sclerosis, is selectively processed by human trypsin 4. FEBS Lett. 580, 545-552. (Pubitemid 43089684)
28. Murray T. J., (2005) Multiple Sclerosis: the History of a Disease. Demo, New York.
29. Nishihara M., Ogura H., Ueda N., et al,. (2007) IL-6-gp130-STAT3 in T cells directs the development of IL-17 + Th with a minimum effect on that of Treg in the steady state. Int. Immunol. 19, 695-702. (Pubitemid 47078714)
30. Oka T., Walkup R. D., Tamada Y., Nakajima E., Tochigi A., Shearer T. R., and, Azuma M., (2006) Amelioration of retinal degeneration and proteolysis in acute ocular hypertensive rats by calpain inhibitor ((1S)-1-((((1S)-1-benzyl-3- cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-me thylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester. Neuroscience 141, 2139-2145.
31. Papenfuss T. L., Rogers C. J., Gienapp I., Yurrita M., McClain M., Damico N., Valo J., Song F., and, Whitacre C. C., (2004) Sex differences in experimental autoimmune encephalomyelitis in multiple murine strains. J. Neuroimmunol. 150, 59-69. (Pubitemid 38481648)
32. Park H., Li Z., Yang X. O., et al,. (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6, 1133-1141. (Pubitemid 41541791)
33. Peterson J. W., Bo L., Mork S., Chang A., and, Trapp B. D., (2001) Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50, 389-400. (Pubitemid 32848742)
34. Poser C. M., and, Brinar V. V., (2004) The nature of multiple sclerosis. Clin. Neurol. Neurosurg. 106, 159-171. (Pubitemid 38716142)
35. Ryu M., Yasuda M., Shi D., et al,. (2011) Critical role of calpain in axonal damage-induced retinal ganglion cell death. J. Neurosci. Res. 90, 802-815.
36. Sato S., Quarles R. H., and, Brady R. O., (1982) Susceptibility of the myelin-associated glycoprotein and basic protein to a neutral protease in highly purified myelin from human and rat brain. J. Neurochem. 39, 97-105. (Pubitemid 12025931)
37. Sato S., Quarles R. H., Brady R. O., and, Tourtellotte W. W., (1984) Elevated neutral protease activity in myelin from brains of patients with multiple sclerosis. Ann. Neurol. 15, 264-267. (Pubitemid 14164742)
38. Schaecher K. E., Shields D. C., and, Banik N. L., (2001) Mechanism of myelin breakdown in experimental demyelination: a putative role for calpain. Neurochem. Res. 26, 731-737. (Pubitemid 32756836)
39. Schaecher K., Goust J. M., and, Banik N. L., (2004) The effects of calpain inhibition on IkB alpha degradation after activation of PBMCs: identification of the calpain cleavage sites. Neurochem. Res. 29, 1443-1451. (Pubitemid 39011333)
40. Sharma A. K., and, Rohrer B., (2007) Sustained elevation of intracellular cGMP causes oxidative stress triggering calpain-mediated apoptosis in photoreceptor degeneration. Curr. Eye Res. 32, 259-269. (Pubitemid 46439684)
41. Shields D. C., and, Banik N. L., (1998a) Putative role of calpain in the pathophysiology of experimental optic neuritis. Exp. Eye Res. 67, 403-410. (Pubitemid 28552961)
42. Shields D. C., and, Banik N. L., (1998b) Upregulation of calpain activity and expression in experimental allergic encephalomyelitis: a putative role for calpain in demyelination. Brain Res. 794, 68-74. (Pubitemid 28298866)
43. Shields D. C., and, Banik N. L., (1999) Pathophysiological role of calpain in experimental demyelination. J. Neurosci. Res. 55, 533-541. (Pubitemid 29117612)
44. Shields D. C., Tyor W. R., Deibler G. E., Hogan E. L., and, Banik N. L., (1998) Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis. Proc. Natl Acad. Sci. USA 95, 5768-5772. (Pubitemid 28224171)
45. Shields D. C., Schaecher K. E., Saido T. C., and, Banik N. L., (1999) A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. Proc. Natl Acad. Sci. USA 96, 11486-11491. (Pubitemid 29487407)
46. Shirasaki Y., Yamaguchi M., and, Miyashita H., (2006) Retinal penetration of calpain inhibitors in rats after oral administration. J. Ocul. Pharmacol. Ther. 22, 417-424. (Pubitemid 46106479)
47. Smith A. W., Das A., Guyton M. K., Ray S. K., Rohrer B., and, Banik N. L., (2011a) Calpain inhibition attenuates apoptosis of retinal ganglion cells in acute optic neuritis. Invest. Ophthalmol. Vis. Sci. 52, 4935-4941.
48. Smith A. W., Doonan B. P., Tyor W. R., Abou-Fayssal N., Haque A., and, Banik N. L., (2011b) Regulation of Th1/Th17 cytokines and IDO gene expression by inhibition of calpain in PBMCs from MS patients. J. Neuroimmunol. 232, 179-185.
49. Tekok-Kilic A., Benedict R. H., and, Zivadinov R., (2006) Update on the relationships between neuropsychological dysfunction and structural MRI in multiple sclerosis. Expert Rev. Neurother. 6, 323-331.
50. Toba S., Tamura Y., Kumamoto K., et al,. (2013) Post-natal treatment by a blood-brain-barrier permeable calpain inhibitor, SNJ1945 rescued defective function in lissencephaly. Sci. Rep. 3, 1224.
51. Trapp B. D., Ransohoff R., and, Rudick R., (1999) Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol. 12, 295-302. (Pubitemid 29378163)
52. Venken K., Hellings N., Broekmans T., Hensen K., Rummens J. L., and, Stinissen P., (2008) Natural naive CD4 + CD25 + CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. J. Immunol. 180, 6411-6420.
53. Venken K., Hellings N., Liblau R., and, Stinissen P., (2010) Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol. Med. 16, 58-68.
54. Wipfler P., Harrer A., Pilz G., Oppermann K., Trinka E., and, Kraus J., (2011) Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options. Drug Discov. Today 16, 8-21.
55. Zheng J., and, Bizzozero O. A., (2011) Decreased activity of the 20S proteasome in the brain white matter and gray matter of patients with multiple sclerosis. J. Neurochem. 117, 143-153.